InvestorsHub Logo
Followers 12
Posts 917
Boards Moderated 0
Alias Born 08/01/2006

Re: None

Wednesday, 01/02/2013 5:10:55 PM

Wednesday, January 02, 2013 5:10:55 PM

Post# of 724
Wondering how much concern to have regarding the company's waiver request for the dermal carcinogenicity study? Seems like there should be enough data to answer the mail, but have certainly seen the FDA be inflexible with supplemental study requirements on other drugs.

GLTA,

Murocman
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PATH News